Preoperatively administered ramosetron oral disintegrating tablets for preventing nausea and vomiting associated with patient-controlled analgesia in breast cancer patients.

Lee, H-J; Kwon, J-Y; Shin, S-W; Kim, C-H; Baek, S-H; Baik, S-W; Kim, H-K; Kim, K-H
European journal of anaesthesiology
2008Sep ; 25 ( 9 ) :756-62.
ÀúÀÚ »ó¼¼Á¤º¸
Lee, H-J -
Kwon, J-Y -
Shin, S-W -
Kim, C-H -
Baek, S-H -
Baik, S-W -
Kim, H-K -
Kim, K-H -
ABSTRACT
BACKGROUND AND OBJECTIVES: The purpose of this study was to investigate the acceptability and therapeutic efficacy of a preoperative single administration of long-acting 5-hydroxytryptamine type 3 (5-HT 3) receptor antagonist in an orally disintegrating tablet formulation, ramosetron, in breast cancer patients.

METHODS: Two hundred and forty women, ASA I-II, aged 24-60 yr, undergoing elective breast cancer surgery, were randomized. A standardized anaesthetic technique was used. Patients were assigned to receive one of three treatment regimens (n = 80 in each group): no prophylactic antiemetics (Group A), single prophylactic intravenous injection of ramosetron 0.1 mg at the completion of surgery (Group B) or preoperatively oral administration of 0.1 mg of ramosetron (Group C). Episodes of nausea and vomiting, the use of rescue antiemetic treatment, degree of pain, adverse events and level of satisfaction were recorded.

RESULTS: The overall incidence of nausea and vomiting during the first 24 h after the recovery in Groups B (27.8%) and C (25%) was decreased significantly compared with Group A (75.3%). The frequency of the use of rescue antiemetics was significantly lower in Group C (5.0%) compared with Groups A (53.2%) and B (15.2%). The patients in Group C were more satisfied with control of postoperative nausea and vomiting than others. CONCLUSION: Preoperative oral administration of ramosetron at a dose of 0.1 mg is an acceptable and effective way of reducing the incidence of postoperative nausea and vomiting in breast cancer patients.
MESH
Administration, Oral, Adult, Analgesia, Patient-Controlled/*adverse effects, Analgesics, Opioid/therapeutic use, Antiemetics/*administration & dosage/adverse effects, Benzimidazoles/*administration & dosage/adverse effects, Breast Neoplasms/surgery, Female, Fentanyl/therapeutic use, Humans, Middle Aged, Pain Measurement, Patient Satisfaction, Postoperative Nausea and Vomiting/*prevention & control, Premedication, Serotonin Antagonists/*administration & dosage/adverse effects, Treatment Outcome
¸µÅ©

ÁÖÁ¦ÄÚµå
ÁÖÁ¦¸í(Target field)
¿¬±¸´ë»ó(Population)
¿¬±¸Âü¿©(Sample size)
´ë»ó¼ºº°(Gender)
Áúº´Æ¯¼º(Condition Category)
¿¬±¸È¯°æ(Setting)
¿¬±¸¼³°è(Study Design)
¿¬±¸±â°£(Period)
ÁßÀç¹æ¹ý(Intervention Type)
ÁßÀç¸íĪ(Intervention Name)
Å°¿öµå(Keyword)
À¯È¿¼º°á°ú(Recomendation)
Preoperative oral administration of ramosetron at a dose of 0.1 mg is an acceptable and effective way of reducing the incidence of postoperative nausea and vomiting in breast cancer patients.
¿¬±¸ºñÁö¿ø(Fund Source)
±Ù°Å¼öÁØÆò°¡(Evidence Hierarchy)
ÃâÆdz⵵(Year)
Âü¿©ÀúÀÚ¼ö(Authors)
´ëÇ¥ÀúÀÚ
DOI
10.1017/S0265021508004262
KCDÄÚµå
ICD 03
°Ç°­º¸ÇèÄÚµå